First Trust Advisors LP raised its position in United Therapeutics Corporation (NASDAQ:UTHR) by 27.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 427,794 shares of the biotechnology company’s stock after buying an additional 91,972 shares during the period. First Trust Advisors LP owned approximately 0.95% of United Therapeutics Corporation worth $55,498,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in UTHR. Focused Wealth Management Inc raised its stake in United Therapeutics Corporation by 17.5% in the first quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock worth $127,000 after buying an additional 140 shares during the period. Advisory Services Network LLC acquired a new stake in United Therapeutics Corporation during the first quarter worth $147,000. Daiwa Securities Group Inc. raised its stake in United Therapeutics Corporation by 17.4% in the first quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock worth $183,000 after buying an additional 200 shares during the period. Campbell & CO Investment Adviser LLC acquired a new stake in United Therapeutics Corporation during the first quarter worth $204,000. Finally, Eagle Global Advisors LLC acquired a new stake in United Therapeutics Corporation during the second quarter worth $206,000.

United Therapeutics Corporation (NASDAQ UTHR) opened at 128.23 on Friday. The company has a 50 day moving average of $130.60 and a 200 day moving average of $135.35. United Therapeutics Corporation has a 12 month low of $110.90 and a 12 month high of $169.89. The stock has a market capitalization of $5.57 billion, a price-to-earnings ratio of 14.87 and a beta of 1.51.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of $3.61 by $4.86. The business had revenue of $444.60 million for the quarter, compared to analysts’ expectations of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. United Therapeutics Corporation’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.42 EPS. On average, equities analysts predict that United Therapeutics Corporation will post $10.70 EPS for the current year.

United Therapeutics Corporation announced that its Board of Directors has authorized a share buyback plan on Thursday, April 27th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the biotechnology company to buy up to 4.6% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/13/first-trust-advisors-lp-increases-stake-in-united-therapeutics-corporation-uthr.html.

A number of analysts recently weighed in on the stock. Jefferies Group LLC reaffirmed a “sell” rating and issued a $105.00 price objective on shares of United Therapeutics Corporation in a research note on Friday, July 14th. ValuEngine lowered shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. BidaskClub lowered shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Cowen and Company reaffirmed a “hold” rating and issued a $121.00 price objective on shares of United Therapeutics Corporation in a research note on Wednesday, April 26th. Finally, UBS AG reissued a “sell” rating and set a $106.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Six equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company’s stock. United Therapeutics Corporation presently has a consensus rating of “Hold” and an average target price of $134.50.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 1,265 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $119.40, for a total value of $151,041.00. Following the completion of the sale, the chief executive officer now owns 1,405 shares in the company, valued at $167,757. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 2,176 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $127.11, for a total value of $276,591.36. Following the completion of the sale, the chief executive officer now owns 3,245 shares of the company’s stock, valued at approximately $412,471.95. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 24,675 shares of company stock valued at $3,181,693. 7.80% of the stock is owned by company insiders.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.